Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
Logo Image
News|Podcasts|May 12, 2026

The BioPharm Brief: Gene Therapy, ADCs, Big Pharma Alliances

Today’s BioPharm Brief covers a major gene therapy milestone, an FDA Breakthrough Therapy designation in rare cancer, and a multi-billion-dollar oncology partnership shaping global drug development pipelines.

Welcome to The BioPharm Brief, your daily news update from BioPharmInternational.com, where we break down the most important developments shaping drug development, regulatory strategy, and biopharma partnerships.

Today’s headlines span rare disease gene therapy, targeted oncology innovation, and one of the largest early-stage collaboration deals announced this year.

AskBio has dosed the first participant in its Phase 1/2 PROGRESS-GT LOPD clinical trial evaluating AB-1009, an adeno-associated virus, or AAV-based gene therapy for late-onset Pompe disease. The investigational therapy is designed to address the underlying genetic cause of Pompe disease by enabling sustained production of the deficient GAA enzyme. The study will enroll approximately 12 adult participants in the United States and will assess safety, tolerability, and early efficacy signals. Current standard of care relies on enzyme replacement therapy, which requires ongoing infusions and may become less effective over time in some patients, highlighting the need for longer-acting treatment approaches.

In oncology, Servier announced that the US Food and Drug Administration has granted Breakthrough Therapy designation to emiltatug ledadotin, an investigational antibody-drug conjugate targeting B7-H4 for the treatment of adenoid cystic carcinoma, or ACC. ACC is a rare and aggressive cancer most commonly originating in the salivary glands, and there are currently no approved systemic therapies for advanced disease. Early Phase 1 data showed antitumor activity across multiple tumor types with a manageable safety profile. The Breakthrough Therapy designation is intended to accelerate the development and regulatory review of therapies that may offer meaningful advantages over existing treatment options.

And in a major industry development, Bristol Myers Squibb and Hengrui Pharma announced a collaboration potentially worth up to $15.2 billion. The agreement covers 13 early-stage programs across oncology, hematology, and immunology, and includes joint development and licensing arrangements designed to advance a broad pipeline of investigational assets. The partnership reflects continued expansion of cross-border deals, particularly between large global pharmaceutical companies and China-based innovators, as companies look to strengthen early-stage pipelines and diversify therapeutic portfolios.

Taken together, today’s updates reflect three defining trends in biopharma: the push toward potentially durable gene therapies in rare disease, increasing use of targeted biologics in hard-to-treat cancers, and continued globalization of early-stage drug development through large strategic partnerships.

Thanks for listening to The BioPharm Brief. For analysis and expert insights, please visit BioPharmInternational.com.

Summary of key developments

  • AskBio initiated dosing in a Phase 1/2 study of AB-1009, an AAV gene therapy for late-onset Pompe disease.
  • Servier received FDA Breakthrough Therapy designation for emiltatug ledadotin in adenoid cystic carcinoma.
  • Bristol Myers Squibb and Hengrui launched a $15.2B collaboration spanning 13 programs in oncology, hematology, and immunology.

Related to this article

View more
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Read more
The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
FDA grants RMAT and Fast Track designations to AbelZeta’s CD20/CD19 bispecific CAR-T prizlon-cel in relapsed or refractory large B-cell lymphoma, Larimar Therapeutics completes a BLA seeking accelerated approval of nomlabofusp for Friedreich’s ataxia, and Merck’s GLP-1/glucagon receptor agonist efinopegdutide meets its primary endpoint in a phase 2b MASH trial.
Read more
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
argenx agrees to acquire macrocyclic peptide developer Unnatural Products for up to about $1.15 billion, Johnson & Johnson’s pasritamig and JNJ-9401 bispecific regimen achieves a 73% PSA response in phase 1 in metastatic castration-resistant prostate cancer, and Janux Therapeutics’ TRBV6-targeted T-cell engager JANX011 shows deep B-cell depletion in healthy volunteers.
Read more
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
FDA grants accelerated approval to Johnson & Johnson’s subcutaneous EGFR/MET bispecific Rybrevant Faspro for previously treated head and neck squamous cell carcinoma, T-Therapeutics raises a $133 million Series B to take TCR-CD3 bispecifics into clinical trials, and Alethio Therapeutics raises a $90 million Series A to advance its first-in-class G6B antibody for essential thrombocythemia.
Read more
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
China’s NMPA grants priority review to Akeso’s PD-1/VEGF bispecific ivonescimab with chemotherapy for first-line biliary tract cancer, VeonGen Therapeutics aligns with FDA on a phase 3 design for its dual-AAV Stargardt gene therapy VG801, and Caldera Therapeutics’ IL-23p19×TL1A bispecific CLD-423 shows a half-life of more than 40 days in a phase 1a trial.
Read more
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
Boehringer Ingelheim licenses six preclinical ADC and T-cell engager programs from Sino Biopharmaceutical in a deal worth up to $7 billion, Spyre Therapeutics drops anti-TL1A antibody SPY072 in rheumatic diseases after phase 2 misses and turns to hidradenitis suppurativa, and Biora Therapeutics gets ethics approval for a first-in-human trial of its BioJet oral adalimumab capsule.
Read more